Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-11 in Orlando, Florida.

Presentations span clinical, translational, and patient-centered research across the Company’s autoimmune focused, off-the-shelf, iPSC-derived CAR T-cell pipeline, including FT819 and FT839. Two FT819 presentations will feature updated clinical data, including administration of FT819 without the use of conditioning chemotherapy, the overview of a unique biomarker association with quality-of-life improvement, and continued progress on outpatient administration to expand community-based access, including in underserved regions. A third presentation details a patient perspective focus group study conducted in collaboration with the Lupus Foundation of America, which explores patient preferences for off-the-shelf, allogeneic CAR T-cell therapy in lupus. The final presentation will provide an update on preclinical studies and the design and progress of the COMPLETE Trial, a recently cleared Phase 1/2 clinical trial of FT839, the company’s off-the-shelf, dual-CAR T-cell product candidate co-targeting CD19 and CD38 for the comprehensive elimination of multicellular drivers of autoimmune diseases, including in rheumatoid arthritis (RA).